These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 29400412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
    Nazreen S, Alam MS, Hamid H, Shahar Yar M, Dhulap A, Alam P, Pasha MA, Bano S, Alam MM, Haider S, Kharbanda C, Ali Y, Pillai K.
    Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
    Nazreen S, Alam MS, Hamid H, Yar MS, Dhulap A, Alam P, Pasha MA, Bano S, Alam MM, Haider S, Kharbanda C, Ali Y, Pillai KK.
    Bioorg Med Chem Lett; 2014 Jul 15; 24(14):3034-42. PubMed ID: 24890090
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
    Naim MJ, Alam MJ, Nawaz F, Naidu VGM, Aaghaz S, Sahu M, Siddiqui N, Alam O.
    Bioorg Chem; 2017 Aug 15; 73():24-36. PubMed ID: 28582649
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
    Nazreen S, Alam MS, Hamid H, Yar MS, Shafi S, Dhulap A, Alam P, Pasha MA, Bano S, Alam MM, Haider S, Ali Y, Kharbanda C, Pillai KK.
    Eur J Med Chem; 2014 Nov 24; 87():175-85. PubMed ID: 25255433
    [Abstract] [Full Text] [Related]

  • 7. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Almanza-Pérez JC, Román-Ramos R, Alarcón-Aguilar FJ, Hernández-Rosado JV, Moreno-Díaz H, Díaz-Coutiño D, Navarrete-Vázquez G.
    Chem Biol Drug Des; 2013 Apr 24; 81(4):474-83. PubMed ID: 23289972
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
    Najmi A, Alam MS, Thangavel N, Taha MME, Meraya AM, Albratty M, Alhazmi HA, Ahsan W, Haque A, Azam F.
    Sci Rep; 2023 Nov 14; 13(1):19869. PubMed ID: 37963936
    [Abstract] [Full Text] [Related]

  • 10. Novel benzenesulfonylureas containing thiophenylpyrazoline moiety as potential antidiabetic and anticancer agents.
    Kharbanda C, Alam MS, Hamid H, Javed K, Shafi S, Ali Y, Alam P, Pasha MA, Dhulap A, Bano S, Nazreen S, Haider S.
    Bioorg Med Chem Lett; 2014 Nov 15; 24(22):5298-303. PubMed ID: 25442322
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of thiazolidine-2,4-dione-pyrazole conjugates as antidiabetic, anti-inflammatory and antioxidant agents.
    Bansal G, Singh S, Monga V, Thanikachalam PV, Chawla P.
    Bioorg Chem; 2019 Nov 15; 92():103271. PubMed ID: 31536952
    [Abstract] [Full Text] [Related]

  • 12. Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
    Kharbanda C, Alam MS, Hamid H, Javed K, Dhulap A, Bano S, Ali Y.
    Bioorg Med Chem Lett; 2015 Oct 15; 25(20):4601-5. PubMed ID: 26384286
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones.
    Chhajed SS, Chaskar S, Kshirsagar SK, Haldar GM, Kar Mahapatra D.
    Comput Biol Chem; 2017 Apr 15; 67():260-265. PubMed ID: 28193552
    [Abstract] [Full Text] [Related]

  • 15. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
    Thangavel N, Bratty MA, Javed SA, Ahsan W, Hazmi HA.
    J Biol Regul Homeost Agents; 2019 Apr 15; 33(3):707-719. PubMed ID: 31204468
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
    Liu K, Zhao X, Qi X, Hou DL, Li HB, Gu YH, Xu QL.
    Eur J Med Chem; 2021 Jun 05; 218():113388. PubMed ID: 33784603
    [Abstract] [Full Text] [Related]

  • 17. Novel Piperine Derivatives with Antidiabetic Effect as PPAR-γ Agonists.
    Kharbanda C, Alam MS, Hamid H, Javed K, Bano S, Ali Y, Dhulap A, Alam P, Pasha MA.
    Chem Biol Drug Des; 2016 Sep 05; 88(3):354-62. PubMed ID: 27037532
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM, Salama I, Mostafa S, Gomaa MS, Helal MA.
    Eur J Med Chem; 2016 Feb 15; 109():157-72. PubMed ID: 26774923
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.